RCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at CSCO
05/09/2025 07:02
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250905:nRSE0751Ya&default-theme=true
RNS Number : 0751Y Hutchmed (China) Limited 05 September 2025
Press Release
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
Hong Kong, Shanghai & Florham Park, NJ - Friday, September 5, 2025:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from
several studies of compounds discovered by HUTCHMED will be presented at the
2025 World Conference on Lung Cancer ("WCLC") taking place on September 6-9,
2025 in Barcelona, Spain, and the Chinese Society of Clinical Oncology
("CSCO") Annual Meeting 2025, taking place on September 10-14, 2025 in Jinan,
China.
Updated analysis from savolitinib's SACHI, SAVANNAH and a Phase IIIb
confirmatory study in non-small cell lung cancer ("NSCLC") patients will be
presented at WCLC 2025. Savolitinib is an oral, potent and highly selective
MET tyrosine kinase inhibitor ("TKI") being jointly developed by AstraZeneca
and HUTCHMED and commercialized by AstraZeneca. Details of the WCLC 2025
presentations are as follows:
Abstract title Presenter / Lead author Presentation details
SPONSORED STUDIES
SAVANNAH: Biomarker Concordance and Acquired Resistance in Patients with EGFRm Christina Baik, University of Washington and Fred Hutchinson Cancer Center, MA03.03 (https://cattendee.abstractsonline.com/meeting/21151/Session/201)
MET-OverExp and / or Amp NSCLC Seattle, USA
Mini Oral: New Advances in Circulating Biomarkers
Room 06
Sunday, September 7, 2025
3:15 - 4:30PM CEST
Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Yongfeng Yu, Shanghai Chest Hospital, Shanghai, China P3.12.48 (https://cattendee.abstractsonline.com/meeting/21151/Session/186)
Patients With or Without Prior Immunotherapy
Poster: Metastatic NSCLC - Targeted Therapy
Tuesday, September 9, 2025
Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation Lijuan Chen, Affiliated Cancer Hospital of Zhengzhou University & Henan P3.12.64 (https://cattendee.abstractsonline.com/meeting/21151/Session/186)
EGFR-TKI Failure: SACHI Study Insights Cancer Hospital, Zhengzhou, China
Poster: Metastatic NSCLC - Targeted Therapy
Tuesday, September 9, 2025
Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp And/Or Amp Silvia Novello, University of Turin, San Luigi Hospital, Turin, Italy PT2.12.04 (https://cattendee.abstractsonline.com/meeting/21151/Session/231)
Post-Progression on Osimertinib: SAVANNAH PROs
ePoster: Metastatic NSCLC - Targeted Therapy
Monday, September 8, 2025
INVESTIGATOR-INITIATED STUDIES
Efficacy and Safety of Surufatinib, Durvalumab in Combined with Chemotherapy Hui Zhang/ Ying Hu, Beijing Chest Hospital, Beijing, China P3.13.22 (https://cattendee.abstractsonline.com/meeting/21151/Session/187)
as First-line Treatment of Extensive-stage Small-cell Lung Cancer
Poster: Small Cell Lung Cancer and Neuroendocrine Tumors
Tuesday, September 9, 2025
Clinical data of HMPL-653, a novel, selective and potent CSF-1R inhibitor,
from a first-in-human Phase I study in patients with tenosynovial giant cell
tumor in China will be presented for the first time at the CSCO Annual Meeting
2025. Details of the CSCO Annual Meeting 2025 presentations are as follows:
Abstract title Presenter / Lead author Presentation details
SPONSORED STUDIES
A first-in-human phase I study of HMPL-653, a CSF-1R inhibitor, in patients Xiaohui Niu 25297
with tenosynovial giant cell tumor
Oral Session
Friday, September 12, 2025
15:00 - 15:12PM HKT
INVESTIGATOR-INITIATED STUDIES
Fruquintinib Plus Serplulimab as First-Line Therapy in Metastatic or Jiwei Huang/ Wei Xue 23258
Unresectable Non-Clear Cell Renal Cell Carcinoma (nccRCC): Updated Efficacy
and Safety from a Multicenter, Single-Arm Trial Oral Session
Thursday, September 11, 2025
16:50 - 17:15PM HKT
Fruquintinib plus camrelizumab combined with paclitaxel liposome and Tianzhu Qiu/ Yanhong Gu 23766
nedaplatin as first-line treatment for advanced esophageal squamous cell
carcinoma (ESCC): updated data from a single-arm, phase II clinical trial Oral Session
Friday, September 12, 2025
11:20 - 12:00 noon HKT
Fruquintinib plus chemotherapy as second-line therapy in metastatic colorectal Yongshun Chen 22084
cancer: a multicenter, open-label, phase II clinical trial
Poster Session
Efficacy and Safety of Neoadjuvant Fruquintinib plus Toripalimab and Zhiping Li 21915
Short-Course Radiotherapy (SCRT) for Locally Advanced Rectal Cancer: Updated
Results from a Phase II Clinical Trial Abstract
Fruquintinib combined with chemotherapy as first-line treatment for advanced Fuxiang Zhou 23550
metastatic colorectal cancer: a propensity score‑matched comparison of
efficacy between a prospective single-arm cohort and a retrospective Abstract
observational cohort
Efficacy and safety of fruquintinib combined with PD-1 inhibitor and chidamide Miaomiao Gou 23591
in MSS mCRC: a comparison with real-world bevacizumab plus anti-pd-1 and
chidamide arm Abstract
Phase ll Clinical Study of Surufatinib Combined with Gemcitabine and Cisplatin Miaomiao Gou 23610
Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary
Tract Cancer Oral Session
Friday, September 12, 2025
16:53 - 16:59PM HKT
A single-arm, Phase Ib/II trial of surufatinib plus KN046 and gemcitabine and Wenquan Wang/ Liang Liu 23783
nab-paclitaxel as first-line treatment for unresectable advanced pancreatic
cancer Oral Session
Thursday, September 11, 2025
16:20 - 16:35PM HKT
Updated results of surufatinib plus transarterial embolization versus Dan Cao 22652
surufatinib monotherapy in neuroendocrine tumor with liver metastasis: a
prospective, randomized, controlled trial Poster Session
Surufatinib in patients with soft tissue myeloma who have failed first-line Yuhong Zhou/ Xi Guo P80
standard chemotherapy or anlotinib: a multicenter, prospective, two-cohort,
phase II clinical study Poster Session
Efficacy and Mechanistic Study of the NASCA Regimen (Surufatinib Combined with Guanghai Dai/ Ru Jia 22309
Camrelizumab, Nab-Paclitaxel, and S‑1) in Advanced Pancreatic Cancer
Patients with Liver Metastasis Abstract
A Phase II, Single-Arm Study of Surufatinib Combined with Zimberelimab and Caixia Wang 23679
Nab-Paclitaxel in Patients with Advanced Triple‑Negative Breast Cancer: Data
Update Abstract
Efficacy and safety of surufatinib combined with gemcitabine, cisplatin and Xuetao Shi/ Jingtao Zhong 24133
immune checkpoint inhibitor for the treatment of unresectable locally advanced
or metastatic intrahepatic cholangiocarcinoma Abstract
Efficacy and Safety of Surufatinib in Patients with Neuroendocrine Neoplasms: Jiang Long 24294
A Multicenter Retrospective Study
Abstract
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the US Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events, including but not limited to its
expectations regarding the therapeutic potential of fruquintinib, surufatinib,
savolitinib and HMPL-653, the further clinical development for fruquintinib,
surufatinib, savolitinib and HMPL-653, its expectations as to whether any
studies on fruquintinib, surufatinib, savolitinib and HMPL-653 would meet
their primary or secondary endpoints, and its expectations as to the timing of
the completion and the release of results from such studies. Such risks and
uncertainties include, among other things, assumptions regarding enrollment
rates and the timing and availability of subjects meeting a study's inclusion
and exclusion criteria; changes to clinical protocols or regulatory
requirements; unexpected adverse events or safety issues; the ability of
fruquintinib, surufatinib, savolitinib and HMPL-653, including as combination
therapies, to meet the primary or secondary endpoint of a study, to obtain
regulatory approval in different jurisdictions and to gain commercial
acceptance after obtaining regulatory approval; the potential markets of
fruquintinib, surufatinib, savolitinib and HMPL-653 for a targeted indication,
and the sufficiency of funding. In addition, as certain studies rely on the
use of other drug products as combination therapeutics, such risks and
uncertainties include assumptions regarding their safety, efficacy, supply and
continued regulatory approval. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. For further discussion of these and
other risks, see HUTCHMED's filings with the US Securities and Exchange
Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.
Medical Information
This press release contains information about products that may not be
available in all countries, or may be available under different trademarks,
for different indications, in different dosages, or in different strengths.
Nothing contained herein should be considered a solicitation, promotion or
advertisement for any prescription drugs including the ones under development.
CONTACTS
Investor Enquiries +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)
Media Enquiries
FTI Consulting - +44 20 3727 1030 / HUTCHMED@fticonsulting.com
(mailto:HUTCHMED@fticonsulting.com)
Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
Brunswick - Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
(mailto:HUTCHMED@brunswickgroup.com)
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
Deutsche Numis Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRABDGDCDDGDGUSRecent news on HUTCHMED (China)
See all newsRCS - Hutchmed China Ltd - HUTCHMED to Present R&D Updates on October 31 2025
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at CSCO
AnnouncementREG - Hutchmed China Ltd - Directorate Change
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Completes Enrollment of Phase III Trial
AnnouncementREG - Hutchmed China Ltd - 2025 Interim Results
Announcement